Novo Nordisk(US:NVO) Globenewswire·2026-02-04 07:00Core Viewpoint - Novo Nordisk A/S is initiating a share repurchase program for 2026, with a total amount of up to DKK 15 billion, starting on 4 February 2026, and a specific program of up to DKK 3.8 billion during the trading period from 4 February 2026 to 4 May 2026 [1]. Group 1: Share Repurchase Program - The share repurchase program aims to reduce the company's share capital and fulfill obligations from share-based incentive programs, allowing for the purchase of a maximum of 400,000,000 B shares of DKK 0.10 during the specified trading period [1]. - An authorization for the company to repurchase its own shares was granted at the Annual General Meeting on 27 March 2025, which is valid until the Annual General Meeting in 2026 [2]. - Continuation of the share repurchase program beyond 26 March 2026 is contingent upon receiving further authorization at the Annual General Meeting in 2026 [2]. Group 2: Regulatory Compliance - The program will be conducted in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council and the Commission Delegated Regulation (EU) 2016/1052, known as the "Safe Harbour Rules" [3]. - Nordea Danmark, a branch of Nordea Bank Abp, Finland, will act as the lead manager for the share repurchase program [3]. Group 3: Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focusing on chronic diseases, particularly diabetes [4]. - The company employs approximately 68,800 people across 80 countries and markets its products in around 170 countries, with its B shares listed on Nasdaq Copenhagen and ADRs on the New York Stock Exchange [4].